RA
AVEO

Royce & Associates’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Royce & Associates’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-21,858
Closed -$402K – 1473
2013
Q4 		$402K Buy
21,858
+5,858
+37% +$117K ﹤0.01% 1251
2013
Q3 		$331K Sell
16,000
-38,000
-70% -$870K ﹤0.01% 1269
2013
Q2 		$1.35M Buy
+54,000
New +$2.31M ﹤0.01% 1113

Other funds holding AVEO

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates's AVEO Position: Q1 2014 in Review

Royce & Associates sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2014, closing a stake of 21,858 shares — an estimated $402K sold.

Royce & Associates first reported a position in AVEO in Q2 2013 and held it in 3 quarters. The position peaked at $1.35M in Q2 2013. 68 funds tracked by Wall St. Rank hold AVEO as of Q1 2014.

  • Royce & Associates reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2014 after selling out during the quarter.
  • Royce & Associates sold 21,858 AVEO Pharmaceuticals, Inc. shares in Q1 2014, an estimated $402K.
  • Royce & Associates first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 3 quarters.
  • Royce & Associates's AVEO Pharmaceuticals, Inc. position peaked at $1.35M in Q2 2013.
  • 68 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2014.

Based on Royce & Associates's 13F filing for Q1 2014, filed 12 May 2014.